More News! Is CRISPR better than TALEN for CAR-T?

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Pranisa Thanatattanon

  • Carl Icahn has seized a stake in BMS as rumours of an acquisition swirl


  • Zykadia, a lung cancer drug from Novartis, has been granted Priority Review by the FDA
  • Minoryx has received Orphan Drug Designation from the FDA as well as the EMA for its lead candidate, MIN-102, for neurodegenerative disease
  • A patient has died in Roche‘s hemophilia trial for ACE910 but an investigator concluded the drug was not responsible
  • Researchers at the Leibniz Institute on Aging have characterised a mechanism of gene inactivation that may prevent aging and cancer
  • Bacteria have been engineered to convert carbon dioxide into methane by researchers at the University of Kent

Eric Gevaert

  • Memorial Sloan Kettering Cancer Center has shown that using CRISPR to engineer CAR-T cells gives them “better stamina” than TALEN-engineered cells.
  • The British Medical Journal has published an article warning of the negative impact of the Trump presidency across the Atlantic
  • Germany is about to allow the sale of GMOs without labelling

Snoop Dogg or Real Dog?


Images from ChrisVanLennepPhoto, Curioso, Eric Gevaert and Pranisa Thanatattanon /

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.